Cyto Pulse, the Karolinska Hospital/Institutet and SMI Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Evaluating a CEA-based Vaccine in Patients with Colorectal Cancer.
|
|
|
| Posted
:
Wed, 04 Nov 2009 17:33:30 GMT |
| Author
:
Cyto Pulse Sciences, Inc.
|
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
| Press Release
News |
Home
|
|
|
|
GLEN BURNIE, Md. - (Business Wire) Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval by the Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with colorectal cancer. The trial will investigate the safety of a DNA vaccine delivered by the Derma Vax™ intradermal electroporation system. The vaccine, which encodes Carcinoembryonic Antigen (CEA), was developed jointly by the Swedish Institute for Infectious Disease Control (SMI)/Karolinska Institutet (KI) and Cyto Pulse. Britta Wahren, M.D., Ph.D., Professor in Clinical Virology at KI/SMI and responsible for the CEA vaccine construct, says “we expect this type of gene delivery to be more immunogenic than previous deliveries. When competing against cancer, one way is to redirect the patient's immune response to eradicate many or all tumor cells in the body.” The trial is sponsored by Prof. Håkan Mellstedt, M.D., Ph.D., and will be conducted at the Department of Oncology/Pathology at the Karolinska University Hospital/Institutet. Principal Investigator Maria Liljefors M.D., Ph.D., and Prof. Håkan Mellstedt say “we have worked with CEA vaccination for very long time and we want to improve the strategy. We are very excited about this technology approach which may strongly enhance the immune response.” “We are pleased to announce this trial as part of ongoing efforts to validate Cyto Pulse technology in the clinic,” said Derin Walters, Cyto Pulse CEO. “Our partners at Karolinska have been instrumental in advancing Derma Vax™ as the leading DNA vaccine delivery platform. Derma Vax™ is designed to be safe, well tolerated, and effective, and we are hopeful the treatment will prove this to be the case.” About Karolinska Hospital/ Institutet Karolinska University Hospital is one of Scandinavia’s premier health facilities. Together with the world-respected Karolinska Institutet (KI), they lead in medical break-throughs in Sweden. KI is one of Europe's largest medical universities. It is also Sweden´s largest centre for medical training and research. About Cyto Pulse Sciences Cyto Pulse Sciences, Inc. is a biomedical device and treatment development company commercializing innovative technology to produce and deliver therapeutics for cancer treatments (immunotherapy), protection against infectious diseases (prophylaxis therapy), and correcting genetic defects (gene therapy). Cyto Pulse technology is used in a wide range of fields including monoclonal antibody discovery, polynucleotide vaccine production, and delivery of polynucleotide (DNA/RNA) vaccines. Additional information on Cyto Pulse is available at the company's website, http://www.cytopulse.com. Cyto Pulse Sciences, Inc. Tim Hurd, 410-787-1890 www.cytopulse.com
|

Copyright © 2008
Business Wire. All rights reserved.
|
|
|
|
|
Related
News
Pacific Safety Products Inc. Announces Fiscal Year 2010 First Quarter Results KANATA, ONTARIO -- 11/26/09 --
Pacific Safety Products Inc. (TSX VENTURE: PSP) ("PSP" or "the Company") today announced consolidated financial results for the three month period ended September 30, 2009.
Recent Developments:
- R..
Explorator Reports Third Quarter 2009 Results TORONTO, ONTARIO -- 11/26/09 --
Explorator Resources Inc. ("Explorator" or the "Company")(TSX VENTURE: EXO) reports its financial results for the three and nine month period ended September 30, 2009. Set out herein are the highlights and an excerpt..
MOSAID Reports Results for Second Quarter Fiscal 2010 and Dividend OTTAWA, ONTARIO -- 11/26/09 --
MOSAID Technologies Incorporated (TSX: MSD) today announced financial results for the second quarter of fiscal 2010, ended October 31, 2009.
-- Q2 revenues of $17.3 million exceeded guidance and were up 26..
SilverCrest Executes Definitive Agreement With Macquarie Bank Limited for US$12.5 Million Project Loan and Hedging Facilities for Santa Elena Project, Mexico VANCOUVER, BRITISH COLUMBIA -- 11/26/09 --
SilverCrest Mines Inc. (TSX VENTURE: SVL)(FRANKFURT: CW5) (the "Company") is pleased to announce it has signed the definitive Project Facility Agreement and related documentation with Macquarie Bank Ltd. o..
CO2 Solution Announces Results of Annual Meeting
Trading symbol: CST
Outstanding shares: 50,261,136
QUEBEC CITY, Nov. 26 - CO2 Solution Inc. ("CO2 Solution" or the "Company") announced today that its 2009 Annual General Meeting (the "Meeting") was...
Focus completes $6.0 million financing
VANCOUVER, Nov. 26 - Focus Ventures Ltd. (TSX-V: FCV.V) is pleased to announce that it has closed its previously announced non-brokered private placement of $6.0 million by issuing 8.0 million units at a price of $...
Southern Arc Receives Exchange Acceptance to Amend the Exercise Price of 4,716,418 Share Purchase Warrants VANCOUVER, BRITISH COLUMBIA -- 11/26/09 --
Southern Arc Minerals Inc. (TSX VENTURE: SA) wishes to announce that it has received TSX Venture Exchange acceptance to amend the exercise price of 4,716,418 share purchase warrants from to $1.75 to $0.70...
|
|
|
|
|
|
|
|
|